Table 3.
Mean (SE) Scores for Cognitive and Affective Measures, by Treatment Group and Visit (N = 1,498)
| Measure | Visit |
P |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
2 |
3 |
||||||||||||
| Tamoxifen(n = 733) |
Raloxifene(n = 765) |
Tamoxifen(n = 475) |
Raloxifene(n = 513) |
Tamoxifen(n = 223) |
Raloxifene(n = 251) |
|||||||||
| Mean | SE | Mean | SE | Mean | SE | Mean | SE | Mean | SE | Mean | SE | Treatment | Visit | |
| Global cognition | ||||||||||||||
| 3MS | 96.3 | 0.12 | 96.3 | 0.12 | 96.9 | 0.13 | 97.0 | 0.12 | 96.9 | 0.17 | 97.2 | 0.15 | .61 | < .0001 |
| Verbal knowledge | ||||||||||||||
| PMA-V | 35.8 | 0.33 | 36.1 | 0.33 | 37.0 | 0.35 | 37.1 | 0.34 | 37.6 | 0.40 | 37.7 | 0.39 | .71 | < .0001 |
| Verbal fluency | ||||||||||||||
| Letter fluency | 38.7 | 0.44 | 38.8 | 0.43 | 39.7 | 0.49 | 40.2 | 0.47 | 39.4 | 0.60 | 40.5 | 0.57 | .56* | < .0001 |
| Semantic fluency | 29.0 | 0.22 | 29.2 | 0.22 | 29.1 | 0.25 | 29.2 | 0.25 | 29.2 | 0.33 | 29.1 | 0.31 | .69 | .96 |
| Memory | ||||||||||||||
| BVRT errors | 6.8 | 0.14 | 6.8 | 0.14 | 6.4 | 0.16 | 6.3 | 0.16 | 6.3 | 0.21 | 5.9 | 0.20 | .70 | < .0001 |
| CVLT | ||||||||||||||
| Total List A trials | 28.0 | 0.23 | 28.4 | 0.22 | 29.2 | 0.26 | 29.6 | 0.25 | 25.8 | 0.34 | 27.0 | 0.32 | .10 | < .0001 |
| Total List B trials | 6.3 | 0.08 | 6.5 | 0.07 | 6.5 | 0.09 | 6.7 | 0.09 | 4.7 | 0.13 | 4.9 | 0.12 | .04 | < .0001 |
| Short-delay free recall | 8.4 | 0.11 | 8.3 | 0.11 | 8.8 | 0.13 | 8.9 | 0.13 | 8.0 | 0.17 | 8.2 | 0.16 | .93 | < .0001 |
| Long-delay free recall | 8.9 | 0.11 | 8.9 | 0.11 | 9.4 | 0.13 | 9.5 | 0.12 | 9.2 | 0.16 | 9.4 | 0.16 | .86 | < .0001 |
| Attention and working memory | ||||||||||||||
| Digits forward | 7.8 | 0.08 | 7.6 | 0.08 | 7.7 | 0.09 | 7.7 | 0.09 | 7.9 | 0.11 | 7.6 | 0.11 | .10 | .88 |
| Digits backward | 6.8 | 0.08 | 6.7 | 0.07 | 6.9 | 0.09 | 6.7 | 0.08 | 6.8 | 0.11 | 6.6 | 0.11 | .08 | .28 |
| Spatial ability | ||||||||||||||
| Card rotations | 57.9 | 1.04 | 57.7 | 1.02 | 63.2 | 1.15 | 63.6 | 1.11 | 65.5 | 1.41 | 64.6 | 1.35 | .93 | < .0001 |
| Fine motor speed | ||||||||||||||
| Finger tapping, dominant | 40.8 | 0.29 | 41.2 | 0.29 | 40.9 | 0.33 | 41.2 | 0.32 | 41.4 | 0.42 | 41.6 | 0.41 | .31 | .18 |
| Finger tapping, nondominant | 38.2 | 0.25 | 38.6 | 0.24 | 38.3 | 0.28 | 38.4 | 0.27 | 38.0 | 0.34 | 38.7 | 0.33 | .24 | .95 |
| Affect | ||||||||||||||
| PANAS-positive | 3.6 | 0.03 | 3.7 | 0.02 | 3.6 | 0.03 | 3.6 | 0.03 | 3.6 | 0.04 | 3.6 | 0.04 | .45 | .01 |
| PANAS-negative | 1.5 | 0.02 | 1.6 | 0.02 | 1.5 | 0.03 | 1.6 | 0.03 | 1.6 | 0.03 | 1.5 | 0.03 | .40 | .64 |
| GDS | 1.4 | 0.08 | 1.4 | 0.07 | 1.5 | 0.09 | 1.4 | 0.09 | 1.7 | 0.12 | 1.6 | 0.11 | .68 | .01 |
NOTE. Scores were adjusted for age, ethnicity, education, prior estrogen use, prior progestin use, and time since last menstrual period.
Abbreviations: SE, standard error of the mean; 3MS, Modified Mini Mental State Examination; PMA-V, Primary Mental Abilities-Vocabulary; BVRT, Benton Visual Retention Test; CVLT, California Verbal Learning Test; PANAS, Positive and Negative Affect Schedule; GDS, Geriatric Depression Scale.
*
Age by treatment interaction (P = .01).